December 12, 2006:
December 12, 2006 : Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is developing NXC-4720, the Company’s innovative new product targeting E.coli O157:H7 food poisoning at its source
November 29, 2006:
November 29, 2006: Nymox announced today that the Company has secured new commitment for $13 million in private equity financing. The private placement of common stock is with institutional investors who have participated in previous successful financings for the company, and is priced at a 3% discount to the market price. There are no warrants with the placement and no restrictions on other corporate financing.
Newly Published Editorial in Expert Opinion on Investigational Drugs Says Statins May Be Good for Alzheimer’s Disease
November 22, 2006:
November 22, 2006: A newly published editorial in Expert Opinion on Investigational Drugs has concluded that statins, the widely used cholesterol drugs, “probably strike at the heart of the sporadic Alzheimer’s disease-inducing mechanism” .
November 20, 2006:
November 20, 2006: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is taking innovative and unique approaches to the diagnosis and treatment of Alzheimer’s disease.
November 17, 2006:
November 17, 2006: November 16 is the American Cancer Society’s Great American Smokeout, when smokers across the U.S. are encouraged to butt out for the day and hopefully for good. Nymox Pharmaceutical Corporation (NASDAQ:NYMX) offers its NicAlert™.
November 13, 2006:
November 13, 2006: Nymox Pharmaceutical Corporation announced today its financial results for the third quarter of 2006.
November 3, 2006:
November 3, 2006: Nymox announced today that Dr. Paul Averback, CEO of Nymox Pharmaceutical, will present at the 29th Annual Westergaard SmallCap Conference on Monday, November 6, 2006.
October 31, 2006:
October 31, 2006: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company is in discussions with potential marketing partners for the Company’s NX-1207 drug for the treatment of benign prostatic hyperplasia (BPH), following the successful completion of a placebo-controlled, double-blind, multi-center Phase 2 trial.